相关实验视频

Updated: May 30, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

引入索福斯布维尔/韦尔帕塔斯维尔 + 里巴维林作为C型肝炎的通用再治疗方案:卢旺达政府计划的评估

Janvier Serumondo¹, Peter Barebwanuwe², Ephrem Daniel Sheferaw²

¹Rwanda Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

|January 29, 2025

概括

索福斯布维尔/韦尔帕塔斯维尔加上里巴维林 (SOF/VEL + RBV) 提供了一个可行的C型肝炎病毒 (HCV) 再治疗选择. 这种疗法在卢旺达的一项计划中实现了75.3%的治愈率,证明了其在资源有限的环境中的潜力.

科学领域:

肝病学肝病学是一种肝病学.
传染性疾病传染性疾病
公共卫生公共卫生

背景情况:

对于初始治疗失败的患者来说,重新治疗C型肝炎病毒 (HCV) 非常重要.
在许多资源有限的环境中,推的sofosbuvir/velpatasvir/voxilaprevir疗法是无法获得的.
全球需要有效和可访问的HCV再治疗策略.

研究的目的:

为了评估sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) 在HCV再治疗中的疗效.
评估政府支持的HCV再治疗计划在资源有限的国家的可行性.
为了确定SOF/VEL + RBV在经过治疗的HCV患者中治愈率.

主要方法:

从2021年11月到2022年10月,卢旺达进行了一项潜在的再治疗计划.
参与者接受了24周的索福斯布维尔/韦尔帕塔斯维尔 + 里巴维林 (SOF/VEL + RBV).
用治疗意向分析计算持续病毒学反应 (治愈) 率.

主要成果:

共有231名参与者参加了HCV再治疗计划.
174名参与者实现了持续的病毒学反应,导致75.3%的治愈率.
在这个人群中,SOF/VEL + RBV疗法通常被很好地容忍.

结论:

索福斯布维尔/韦尔帕塔斯维尔 + 里巴维林 (SOF/VEL + RBV) 是C型肝炎病毒 (HCV) 感染的有效再治疗选择.
这种制度可以在资源有限的环境中成功实施,卢旺达计划证明了这一点.
在没有标准疗法的情况下,SOF/VEL + RBV为HCV再治疗提供了一个有希望的替代方案.

关键词:

肝炎C病毒 (HCV) 是一种治疗治疗治疗治疗进行再处理.第二行第二行.治疗失败的治疗失败.

更多相关视频

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...